| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/05/2013 | US8389484 Methods for targeting RNA molecules |
| 03/05/2013 | US8389006 Pharmaceutical compositions of adsorbates of amorphous drug |
| 03/05/2013 | US8388977 Diagnosis of macrophage mediated disease |
| 03/05/2013 | US8388943 Multipotent stem cells from peripheral tissues and uses thereof |
| 03/05/2013 | US8388935 Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| 03/05/2013 | CA2711655C Condensed aminodihydrothiazine derivative |
| 03/05/2013 | CA2666258C Antidepressant, neuroprotectant, amyloid .beta. deposition inhibitor or age retardant containing heterocyclic compound having specific structure |
| 03/05/2013 | CA2628031C Once-daily administration of central nervous system drugs |
| 03/05/2013 | CA2574193C Benzothiazole derivatives as adenosine receptor ligands |
| 03/05/2013 | CA2567703C 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
| 03/05/2013 | CA2539033C Treatment of disease or injury of the nervous system with fty720 |
| 03/05/2013 | CA2529320C Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases |
| 03/05/2013 | CA2427161C Use of bisphosphonates for pain treatment |
| 02/28/2013 | WO2013028909A1 Combination therapy for the treatment of sleep-related breathing disorders |
| 02/28/2013 | WO2013028587A1 1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands |
| 02/28/2013 | WO2013027986A2 Method of screening for chaperonin modulator |
| 02/28/2013 | WO2013027794A1 Novel compound and use thereof as pde10 inhibitor |
| 02/28/2013 | WO2013027188A1 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors |
| 02/28/2013 | WO2013027150A1 Compositions and methods for the treatment of parkinson's disease |
| 02/28/2013 | WO2013027001A1 Compounds and their use to treat histamine h3 related disorders |
| 02/28/2013 | WO2013027000A1 Pyridazinone compounds and their use as daao inhibitors |
| 02/28/2013 | WO2013026896A1 Peptide agent for enhanced drug delivery for improved peripheral analgesia |
| 02/28/2013 | WO2013026852A2 Derivatives of mecamylamine |
| 02/28/2013 | WO2013026806A1 Dyrk1 inhibitors and uses thereof |
| 02/28/2013 | WO2013026787A1 Fentanyl derivatives as ph-dependent opioid receptor agonists |
| 02/28/2013 | WO2013026547A1 Rotigotine in the treatment of hemispatial neglect and other deficits following stroke |
| 02/28/2013 | WO2013026455A1 Permanently positively charged antidepressants |
| 02/28/2013 | WO2013026264A1 Cb1 acceptor inhibitor compound with nitrogen-containing aromatic ring having hydroxyl and use thereof |
| 02/28/2013 | WO2013026151A1 Improved stevia rebaudiana extract and formulation, and uses thereof |
| 02/28/2013 | WO2012154837A9 The use of ketone esters for prevention of cns oxygen toxicity |
| 02/28/2013 | WO2012141615A3 Medicament |
| 02/28/2013 | WO2012125544A3 Necroptosis inhibitors and methods of use therefor |
| 02/28/2013 | WO2012116290A3 Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| 02/28/2013 | WO2012106524A3 Diagnosis and treatment of the prodromal schizophrenic state |
| 02/28/2013 | US20130053450 Treatment of pervasive developmental disorders with redox-active therapeutics |
| 02/28/2013 | US20130053448 Therapeutic Regimens |
| 02/28/2013 | US20130053446 Pharmaceutical preparations having individualized dosage and structure |
| 02/28/2013 | US20130053441 Novel ester derivative and use thereof |
| 02/28/2013 | US20130053438 Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity |
| 02/28/2013 | US20130053435 Methods of Treating Alcohol Intoxication, Alcohol Use Disorders and Alcohol Abuse Which Comprises the Administration of Dihydromyricetin |
| 02/28/2013 | US20130053428 Natural antisense and non-coding rna transcripts as drug targets |
| 02/28/2013 | US20130053420 Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients With Demyelinating and Other Nervous System Conditions |
| 02/28/2013 | US20130053416 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| 02/28/2013 | US20130053414 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 02/28/2013 | US20130053412 Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
| 02/28/2013 | US20130053405 Carrier linked paliperidone prodrugs |
| 02/28/2013 | US20130053402 Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals |
| 02/28/2013 | US20130053398 Modulators of fatty acid amide hydrolase |
| 02/28/2013 | US20130053395 Pyrazolopyridine kinase inhibitors |
| 02/28/2013 | US20130053394 Pyrazolopyrimidine kinase inhibitors |
| 02/28/2013 | US20130053393 Methods and compositions for treating peripheral vascular disease |
| 02/28/2013 | US20130053389 Certain chemical entities, compositions and methods |
| 02/28/2013 | US20130053388 Pyrazolopyrazine kinase inhibitors |
| 02/28/2013 | US20130053386 Diaryl ether derivatives as notch sparing gamma secretase inhibitors |
| 02/28/2013 | US20130053381 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives |
| 02/28/2013 | US20130053380 Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease |
| 02/28/2013 | US20130053379 4-aryl-2-anilino-pyrimidines |
| 02/28/2013 | US20130053377 Inhibitors of beta-secretase |
| 02/28/2013 | US20130053373 Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds |
| 02/28/2013 | US20130053372 5-ht receptor modulators |
| 02/28/2013 | US20130053371 Inhibitors of pi3 kinase |
| 02/28/2013 | US20130053368 Methods for treatment of parkinson's disease |
| 02/28/2013 | US20130053365 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| 02/28/2013 | US20130053363 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE |
| 02/28/2013 | US20130053361 Therapeutic isoxazole compounds |
| 02/28/2013 | US20130053360 Controlled release and taste masking oral pharmaceutical composition |
| 02/28/2013 | US20130053359 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES |
| 02/28/2013 | US20130053358 Transdermally absorbable donepezil-containing preparation |
| 02/28/2013 | US20130053356 2-methylene-19,23,24-trinor-1alpha-hydroxyvitamin d3 |
| 02/28/2013 | US20130053350 Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| 02/28/2013 | US20130053346 Pyrimido-pyridazinone compounds and methods of use thereof |
| 02/28/2013 | US20130053345 Bicyclic heteroarly analogues as gpr119 modulators |
| 02/28/2013 | US20130053344 Synthesis of pyrrolidine compounds |
| 02/28/2013 | US20130053341 Therapeutic compounds and related methods of use |
| 02/28/2013 | US20130053325 Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof |
| 02/28/2013 | US20130053324 Novel self-assembling peptides and their use in the formation of hydrogels |
| 02/28/2013 | US20130053321 Inhibitors of mitochondrial fission and methods of use thereof |
| 02/28/2013 | US20130053315 Novel glp-1 derivatives |
| 02/28/2013 | US20130053308 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 02/28/2013 | US20130053304 Glucagon-like peptide-1 analogues and uses thereof |
| 02/28/2013 | US20130053303 Compounds for enzyme inhibition |
| 02/28/2013 | US20130053301 Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| 02/28/2013 | US20130052737 Method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 02/28/2013 | US20130052281 Novel compounds |
| 02/28/2013 | US20130052279 Reverse micelle system comprising metal ions and use thereof |
| 02/28/2013 | US20130052271 Compositions and Methods for Treating Pain |
| 02/28/2013 | US20130052268 Compositions and methods for treatment of parkinson's disease |
| 02/28/2013 | US20130052267 Methods of Inducing Tissue Regeneration |
| 02/28/2013 | US20130052253 Flavoring of drug-containing chewing gums |
| 02/28/2013 | US20130052234 Edible strips |
| 02/28/2013 | US20130052210 Use of ccl1 in therapy |
| 02/28/2013 | US20130052205 Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
| 02/28/2013 | US20130052203 In vivo screening models for treatment of qc-related disorders |
| 02/28/2013 | US20130052200 Naturally occurring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| 02/28/2013 | US20130052188 Systems and methods for obtaining immunoglobulin from blood |
| 02/28/2013 | US20130052184 Gelatinase inhibitors and prodrugs |
| 02/28/2013 | US20130052179 Arginine deiminase mutant and preparation and application thereof |
| 02/28/2013 | US20130052174 Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
| 02/28/2013 | US20130052170 Grafting material for genetic and cell therapy |
| 02/28/2013 | US20130052169 Stem cell bank for personalized medicine |